RARX - Ra Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
46.60
-0.10 (-0.21%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close46.70
Open46.70
Bid0.00 x 1000
Ask0.00 x 1200
Day's Range46.56 - 46.71
52 Week Range13.73 - 47.35
Volume358,860
Avg. Volume1,064,009
Market Cap2.192B
Beta (3Y Monthly)1.55
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Is Ra Pharmaceuticals, Inc. (RARX) Going To Burn These Hedge Funds ?
    Insider Monkey

    Is Ra Pharmaceuticals, Inc. (RARX) Going To Burn These Hedge Funds ?

    Reputable billionaire investors such as Jim Simons, Cliff Asness and David Tepper generate exorbitant profits for their wealthy accredited investors (a minimum of $1 million in investable assets would be required to invest in a hedge fund and most successful hedge funds won't accept your savings unless you commit at least $5 million) by pinpointing […]

  • Barrons.com

    Stock Holdings in Callon Petroleum, Ra Pharmaceuticals, and More

    Sizing up the ForeScout Technologies’ holdings of Jericho Capital Asset Management and Corvex Management

  • Benzinga

    A Look At Benzinga Pro's Most-Searched Tickers For October 11, 2019

    This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Roku (NASDAQ: ROKU ) shares were up 5.5% to ...

  • Company News For Oct 11, 2019
    Zacks

    Company News For Oct 11, 2019

    Companies in the news are: RARX, BBBY, PCG, MITO

  • This Biotech Stock Just Doubled After Snagging A $2.1 Billion Takeover Deal
    Investor's Business Daily

    This Biotech Stock Just Doubled After Snagging A $2.1 Billion Takeover Deal

    Ra Pharma stock rocketed by more than 100% Thursday after Belgium biotech company UCB agreed to acquire it for $2.1 billion. Ra Pharma is working on a treatment for a muscular condition.

  • 4 Stocks With More Than 20% Price Increases on Thursday
    GuruFocus.com

    4 Stocks With More Than 20% Price Increases on Thursday

    Markets soar on US-China trade talk optimism Continue reading...

  • Ra Pharma acquired for $2.1B by Belgian firm that vows to grow in Boston
    American City Business Journals

    Ra Pharma acquired for $2.1B by Belgian firm that vows to grow in Boston

    The Cambridge biotech, which is in late-stage trials of a drug to treat a rare muscle disease, has been acquired by Belgium-based UCB for $2.1 billion, immediately doubling the market value of the Cambridge firm.

  • Benzinga

    Ra Pharma Stock Doubles On $2.5B Buyout Deal With Belgian Biopharma UCB

    Ra Pharm is a clinical-stage biopharma engaged in the development of therapies for serious diseases caused by excessive activation of the complement system, a critical component of the innate immune system. UCB is paying $48 per share in cash for the company, or $2.5 billion. Net of Ra Pharma's cash, the transaction is valued at $2.1 billion.

  • Benzinga

    The Daily Biotech Pulse: UCB To Buy Ra Pharma, Reata Reacquires Rights To Nrf2 Activators From AbbVie, BioNTech IPO

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 9) Aprea Therapeutics Inc (NASDAQ: APRE ) (IPOed Oct. 3) ...

  • MarketWatch

    Belgium's UCB to acquire Ra Pharma in cash deal valued at about $2.5 billion

    Belgian biopharma company UCB has agreed to acquire Ra Pharmaceuticals Inc. in a cash deal valued at about $2.5 billion, the companies said Thursday. Ra Pharma shareholders will receive $48 per share, equal to a 93% premium over the 30-day volume weighted closing stock price of Ra Pharma prior to signing. The deal has been approved by the boards of both companies and is expected to close by the end of the first quarter of 2020. Cambridge, Mass-based Ra Pharma is a clinical-stage biopharma company focused on development treatments for serious diseases caused by the immune system. "The company's ExtremeDiversity(TM) platform enables the production of synthetic macrocyclic peptides combining the diversity and specificity of antibodies with the pharmacological properties of small molecules," said the statement. The company's phase 3 product candidate zilucoplan had positive results in a phase 2 trial as a treatment for myasthenia gravis, of gMG, a chronic auto-immune condition in which auto-antibodies attack specific proteins in the neuro-muscular junction. That causes muscle weakness and fatigue and affects almost 200,000 patients in the U.S., EU and Japan, said the statement. Ra Pharma shares rose 107% in premarket trade on the news, and are up 25% in 2019 through Wednesday, while the S&P 500 has gained 16%.

  • [video]RA Pharmaceuticals Soars on Deal to Be Acquired for $2.1 Billion
    TheStreet.com

    [video]RA Pharmaceuticals Soars on Deal to Be Acquired for $2.1 Billion

    Shares of biotech company Ra Pharmaceuticals more than double after Belgian-based biotech firm UCB announces it is acquiring the company for $2.1 billion in cash.

  • MarketWatch

    UCB to acquire Ra Pharmaceuticals in $2.1 billion deal

    Shareholders of Ra Pharma will receive $48 for each share held, a joint statement by the two companies said Thursday.

  • Reuters

    UPDATE 1-Belgium's UCB to buy Ra Pharmaceuticals in $2.1 bln cash deal

    UCB has agreed to acquire U.S.-based Ra Pharmaceuticals for $2.1 billion, both companies reported on Thursday, in a deal that will enable the Belgian drugmaker to offer new treatment opportunities for several rare diseases in neurology and immunology. "Ra Pharma is an excellent strategic fit addressing multiple areas of UCB's patient value growth strategy," UCB's Chief Executive Officer Jean-Christophe Tellier said in a joint statement. The acquisition of the clinical-stage biopharmaceutical company, which was founded in 2008, is expected to contribute to UCB's core earning per share and increase its revenue and net profit from 2024 onwards.

  • Benzinga

    The Daily Biotech Pulse: Acadia Schizophrenia Drug Fails, Viveve Plummets, Eisai Gets Breakthrough Therapy Designation

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 22) Acasti Pharma Inc (NASDAQ: ACST ) Apellis Pharmaceuticals ...

  • Hedge Funds Have Never Been This Bullish On Ra Pharmaceuticals, Inc. (RARX)
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On Ra Pharmaceuticals, Inc. (RARX)

    How do we determine whether Ra Pharmaceuticals, Inc. (NASDAQ:RARX) makes for a good investment at the moment? We analyze the sentiment of a select group of the very best investors in the world, who spend immense amounts of time and resources studying companies. They may not always be right (no one is), but data shows […]

  • Ra Pharmaceuticals Closes End-of-Phase 2 Interaction with FDA
    Zacks

    Ra Pharmaceuticals Closes End-of-Phase 2 Interaction with FDA

    Ra Pharmaceuticals (RARX) closes the End-of-Phase II interactions with the FDA for its phase III study on zilucoplan for the treatment of generalized myasthenia gravis (gMG).

  • InvestorPlace

    5 Clinical-Stage Biotech Stocks to Buy

    Last year was not kind to many biotech stocks. When investors abandoned high growth equities as the economy and market got rocky, biotech stocks were some of the first to go. This was especially true for many of the clinical-stage drug developers with no actually marketed products under their belts. The equal-weighted SPDR S&P Biotech (NYSEArca:XBI) -- which has a high concentration of smaller biotech stocks -- managed to lose around 24% in 2018.Investors clearly were not willing to gamble on those smaller stocks that don't have revenues.But the new year is shaping to be a bit better for biotech stocks in general and those clinical-stage developers. So far, risk has once again returned to the menu and the effects of the government shutdown on the FDA are no longer an issue. Investors have once again taken a shine to early-stage drug developers. The XBI is up more than 16% year-to-date.InvestorPlace - Stock Market News, Stock Advice & Trading TipsAnd more gains could be in store for the clinical biotech stocks. * 7 Cheap Stocks That Make the Grade Even better is that, prices for many of the earlier developers remain below their peaks. This gives investors plenty of chances to snag-up some promising drug firms with some serious potential under their belts. But which ones to buy? Here are five clinical stage biotech stocks to buy today. Nightstar Therapeutics (NITE)One of the hottest trends in biotech stocks is gene therapy. There are thousands of diseases and disorders are caused by faulty genes. In a nutshell, gene therapy is fixing those problems by either adding new genes to fight faulty ones, replacing/editing missing/broken genes or actually "turning off" the genes causing problems. It's a major breakthrough and is just starting to get critical mass with the FDA and drug makers.On the ground floor of that is Nightstar Therapeutics (NASDAQ:NITE). NITE's main focus is on gene therapies for patients who suffer from rare inherited retinal diseases that would otherwise progress to blindness. The biotech has several candidates in various trials. It's lead product targeting a condition called choroideremia begun enrolling for phase 3 trials. Choroideremia is a rare disease that has no current treatments. Data so far for NITE's work here has been more than promising and has received several fast-track FDA designations based on early data.But NITE isn't done yet.The clinical stage biotech stock's work on X-Linked Retinitis Pigmentosa -- another genetic eye disease -- has proven successful as well. Nightstar was successful in its "proof of concept" during the fall of last year. Phase 2/3 data is expected in mid-2019.Both of these as well as NITE's full pipeline of other therapies could be very fruitful for investors over the next few years. And that makes the biotech stock a big buy. Ra Pharmaceuticals Inc. (RARX)Clinical biotech stocks can win if they are able to offer something better than established treatments. That's exactly Ra Pharmaceuticals' (NASDAQ:RARX) bag.Generalized Myasthenia Gravis (gMG) is a serious condition that progressively weakens muscles. It's rare and only around 60,000 Americans suffer from the disorder. The only drug approved to treat is the insanely priced Soliris. Soliris and its hefty price tag have allowed Alexion Pharmaceuticals (NASDAQ:ALXN) to reap billions in revenues. But that might end if RARX has its way.At the end of last year, RARX's lead therapy zilucoplan posted amazing phase 2 results for gMG. Digging into the data, Ra's drug was able to improve patients' quantitative MG scores by 6 points. Soliris was approved after improving patients scores by just 4.6 points. Now, that Soliris improvement was at a much great rate than those receiving a placebo, RA wasn't too far behind. What it really means is that RARX should be able to meet with the FDA to discuss the design of a phase 3 trial and work towards getting the drug approved.With a strong balance sheet and continued insider stock purchases, Ra Pharmaceuticals has plenty of potential to pay for that trial and actually see it to the end. * 5 Dow Jones Stocks That Will Lead the Market Higher For investors, with blockbuster replacement looming, RARX stock is alone biotech that shouldn't' be missed. Aurinia Pharmaceuticals (AUPH)Clinical stage biotech stocks tend to be gambles. That's sort of the situation with Aurinia Pharmaceuticals (NASDAQ:AUPH). A ton hinges on a late-stage trial reporting at the end of the year. However, it's a gamble that may be worth looking at.For AUPH, the mission remains to tackle lupus. Lupus remains one of the least understood auto-immune diseases. With lupus, the body's immune system mistakenly attacks healthy tissue. That's pretty bad by itself, however, many people often develop lupus nephritis (LN) and succumb to life-threatening kidney damage. Aurinia is developing a compound called voclosporin works by inhibiting an enzyme that activates immune cells. Voclosporin worked amazingly in phase 2 trials and had a high rate of success for LN patients.Aurinia should wrap phase 3 trials for the drug and LN treatments at the end of 2019. If it hits, analysts now peg sales of the medicine to fetch around $1 billion annually. Naturally, investors have placed a lot of stock on the drug and AUPH's potential. If it hits, investors could be looking at huge blockbuster and a sharp increase in AUPH stock.And if it doesn't, Aurinia may be ok as the firm is developing voclosporin for various indications as well. But given the potential, the firm may be one of the best clinical biotech stocks to buy for a gamble. Arena Pharmaceuticals (ARNA)Partnerships can mean big things for clinical stage biotech stocks. A prime example is Arena Pharmaceuticals (NASDAQ:ARNA).For starters, ARNA has a rich pipeline of treatments in mid-to-late stages of trials. This includes drugs for Ulcerative Colitis, Crohn's Disease, and IBS. That alone is worth the price of admission. But where Arena could be winning is in its drug Ralinepag. Ralinepag has been touted as potentially a best-in-class medicine for treating pulmonary arterial hypertension. So, naturally, any biotech firm that has drugs already on the market that could be threatened by the future blockbuster is willing to bend over backward to defend their position.And that's just United Therapeutics (NASDAQ:UTHR) did by paying Arena $800 million cash up-front as well as up to $400 million in milestone payments and double-digit royalties on sales in order to license Ralinepag.For Arena, this is a win-win. They get cash to develop it and other drugs in their platform and still are able to share in the long-term success of the drug. For investors, this is a big win as well and shows that ARNA's management is thinking about the total portfolio and not just one drug. * 5 Big-Yield REITs to Check Out Now In the end, Arena should have enough money to make its pipeline a reality and get more of its drugs out to market. That makes the clinical biotech stock one to bet on. Galapagos (GLPG)When it comes to late-stage biotech stocks or really any drug manufacturer, pipeline means everything. It's what drives your valuation and future potential. Luckily for clinical-stage firm Galapagos (NASDAQ:GLPG), its pipeline is very robust indeed. GLPG has multiple late-stage programs as well as 25 different drugs in discovery/early trial stages. But what separates Galapagos is that that pipeline is actually churning out real results.Partnering with biotech-giant Gilead (NASDAQ:GILD), GLPG's Filgotinib is quickly becoming a winner and after impressive phase-3 data, the duo has moved closer to marketing the drug rheumatoid arthritis. At the same time, Galapagos has scored wins in cystic fibrosis, idiopathic pulmonary fibrosis, systemic sclerosis and a fast-track designation for its osteoarthritis treatment.All in all, GLPG has many shots on goal to make it. That's very important to a clinical-stage biotech stock. And yet, last years rout of the sector sent shares of GLPG downwards and they've stayed that way. Today, Galapagos is still about 17% below its 2018 peak of $117 per share.Given its huge pipeline -- that is increasingly winning in trials -- that difference may not last long. When it comes to clinical stage biotech stocks, GLPG is one you must own.Disclosure: At the time of writing, Aaron Levitt was Long the iShares Nasdaq Biotechnology ETF -- which holds a position in GILD, ALXN, AUPH, GLPG, RARX, UTHR and ARNACompare Brokers The post 5 Clinical-Stage Biotech Stocks to Buy appeared first on InvestorPlace.

  • Hedge Funds Are Betting On Ra Pharmaceuticals, Inc. (RARX)
    Insider Monkey

    Hedge Funds Are Betting On Ra Pharmaceuticals, Inc. (RARX)

    Before we spend days researching a stock idea we’d like to take a look at how hedge funds and billionaire investors recently traded that stock. S&P 500 Index ETF (SPY) lost 8.7% through October 26th. Forty percent of the S&P 500 constituents were down more than 10%. The average return of a randomly picked stock […]

  • Benzinga

    The Daily Biotech Pulse: Management Change At Merck, Jazz Buyback, Arrowhead Earnings

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 10) Homology Medicines Inc (NASDAQ: FIXX ) OvaScience Inc ...

  • Why Nutrisystem, Xperi, and Ra Pharmaceuticals Jumped Today
    Motley Fool

    Why Nutrisystem, Xperi, and Ra Pharmaceuticals Jumped Today

    Find out which of these stocks got a buyout bid.

  • Here's Why Ra Pharmaceuticals Inc. Is Soaring Today
    Motley Fool

    Here's Why Ra Pharmaceuticals Inc. Is Soaring Today

    Investors are cheering for successful results from a mid-stage trial with the company's lead candidate.

  • Benzinga

    Ra Pharma Shares Rally: What You Need To Know

    Ra Pharmaceuticals Inc (NASDAQ: RARX ) shares are surging higher Monday morning, reacting to an announcement by the company concerning clinical trial results of its autoimmune disorder drug. What Happened ...